The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
DDI has recently joined Twitter. For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: http://twitter.com/fda_drug_info.
We plan to provide updates when new information pertaining to drug products is posted to the FDA web site. DDI believes Twitter will be an invaluable resource to provide timely, accurate information to consumers, healthcare providers, and industry.
We recognize that new communication tools like Twitter derive much of their value from the two-way conversations that they enable, however DDI is only able to send out informational updates. To contact DDI, please email druginfo@xxxxxxxxxxx.
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday. You can also email us at druginfo@xxxxxxxxxxx.
For additional drug information, please visit the DDI Web page: (http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm082585.htm.)
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
